Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

ID#: NCT07575399

Age: 18 - 99 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: May 11, 2026

End Date: February 28, 2028

Contact Information:
Amgen Call Center
866-572-6436
Summary: Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Eligibility:

Inclusion Criteria:

- Body Mass Index (BMI) ≥ 25 at screening.

- Weight loss of ≥ 10% on weekly GLP-1 RA.

- Stable body weight.

- Stable dose of GLP-1RA.

- Stable gastrointestinal (GI) tolerability.

- Contraception for females.

- Willingness to follow trial procedures for the duration of the trial.

Exclusion Criteria:

- Obesity induced by other endocrine disorders (ex: Cushing's syndrome).

- Previous or planned surgical, endoscopic or device-based treatment for obesity.

- History of malignancy.

- Type 1/Type 2 diabetes mellitus (DM).

- Family or personal history of medullary thyroid cancer.

- Previous participation in a Maridebart Cafraglutide trial.
Find a Clinical Trial Find Cancer Clinical Trials